IBDEI3BV ; ; 04-FEB-2020
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
 Q:'DIFQR(358.4)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.4,2180,0)
 ;;=SOCIAL ENVIRONMENT PROBLEMS^29^164
 ;;^UTILITY(U,$J,358.4,2181,0)
 ;;=PARAPHILIC DISORDERS^21^164
 ;;^UTILITY(U,$J,358.4,2182,0)
 ;;=PERSONALITY DISORDERS^23^164
 ;;^UTILITY(U,$J,358.4,2183,0)
 ;;=CRIME/LEGAL SYSTEM PROBLEMS^6^164
 ;;^UTILITY(U,$J,358.4,2184,0)
 ;;=PSYCHOSOCIAL/PERSONAL/ENVIRONMENTAL^24^164
 ;;^UTILITY(U,$J,358.4,2185,0)
 ;;=RELATIONAL PROBLEMS^25^164
 ;;^UTILITY(U,$J,358.4,2186,0)
 ;;=SCHIZOPHRENIA/OTH PSYCHOTIC DISORDERS^26^164
 ;;^UTILITY(U,$J,358.4,2187,0)
 ;;=SEXUAL DYSFUNCTIONS^27^164
 ;;^UTILITY(U,$J,358.4,2188,0)
 ;;=SLEEP-WAKE DISORDERS^28^164
 ;;^UTILITY(U,$J,358.4,2189,0)
 ;;=SUBSTANCE DISORDER-ALCOHOL^31^164
 ;;^UTILITY(U,$J,358.4,2190,0)
 ;;=SUBSTANCE DISORDER-CANNABIS^33^164
 ;;^UTILITY(U,$J,358.4,2191,0)
 ;;=SUBSTANCE DISORDER-HALLUCINOGEN^34^164
 ;;^UTILITY(U,$J,358.4,2192,0)
 ;;=SUBSTANCE DISORDER-OPIOID^36^164
 ;;^UTILITY(U,$J,358.4,2193,0)
 ;;=SUBSTANCE DISORDER-SEDATIVE/HYPNOTIC^37^164
 ;;^UTILITY(U,$J,358.4,2194,0)
 ;;=SUBSTANCE DISORDER-TOBACCO^39^164
 ;;^UTILITY(U,$J,358.4,2195,0)
 ;;=TRAUMA/STRESSOR-RELATED DISORDERS^42^164
 ;;^UTILITY(U,$J,358.4,2196,0)
 ;;=SUBSTANCE DISORDER-INHALANT^35^164
 ;;^UTILITY(U,$J,358.4,2197,0)
 ;;=CLINICAL RESEARCH PROGRAM^4^164
 ;;^UTILITY(U,$J,358.4,2198,0)
 ;;=SOMATIC SYMPTOM & RELATED DISORDERS^30^164
 ;;^UTILITY(U,$J,358.4,2199,0)
 ;;=DISRUPTIVE,IMPULSE,CONDUCT D/O^8^164
 ;;^UTILITY(U,$J,358.4,2200,0)
 ;;=ELIMINATION DISORDERS^11^164
 ;;^UTILITY(U,$J,358.4,2201,0)
 ;;=GAMBLING DISORDER^13^164
 ;;^UTILITY(U,$J,358.4,2202,0)
 ;;=OTHER MENTAL DISORDERS^20^164
 ;;^UTILITY(U,$J,358.4,2203,0)
 ;;=NEURODEVELOPMENTAL DISORDERS^18^164
 ;;^UTILITY(U,$J,358.4,2204,0)
 ;;=SUBSTANCE DISORDER-CAFFEINE^32^164
 ;;^UTILITY(U,$J,358.4,2205,0)
 ;;=SUICIDAL IDEATIONS/ATTEMPTS^41^164
 ;;^UTILITY(U,$J,358.4,2206,0)
 ;;=SUBSTANCE DISORDER-UNKNOWN SUBSTANCE^40^164
 ;;^UTILITY(U,$J,358.4,2207,0)
 ;;=SUBSTANCE DISORDER-STIMULANTS^38^164
 ;;^UTILITY(U,$J,358.4,2208,0)
 ;;=UNDERDOSING OF MEDICATION REGIMEN^43^164
 ;;^UTILITY(U,$J,358.4,2209,0)
 ;;=NEW PATIENT^2^165
 ;;^UTILITY(U,$J,358.4,2210,0)
 ;;=ESTABLISHED PATIENT^1^165
 ;;^UTILITY(U,$J,358.4,2211,0)
 ;;=CONSULTATIONS^3^165
 ;;^UTILITY(U,$J,358.4,2212,0)
 ;;=IMMUNIZATIONS^8^166
 ;;^UTILITY(U,$J,358.4,2213,0)
 ;;=COUNSELING^4^166
 ;;^UTILITY(U,$J,358.4,2214,0)
 ;;=EDUCATION^5^166
 ;;^UTILITY(U,$J,358.4,2215,0)
 ;;=EVALUATIONS^6^166
 ;;^UTILITY(U,$J,358.4,2216,0)
 ;;=IMMUNIZATION ADMINISTRATION^7^166
 ;;^UTILITY(U,$J,358.4,2217,0)
 ;;=TREATMENT PROCEDURES^12^166
 ;;^UTILITY(U,$J,358.4,2218,0)
 ;;=INJECTIONS^9^166
 ;;^UTILITY(U,$J,358.4,2219,0)
 ;;=PROLONGED CLINICAL STAFF SERVICES^10^166
 ;;^UTILITY(U,$J,358.4,2220,0)
 ;;=CARE MGMT FOR BEH HLTH COND^1^166
 ;;^UTILITY(U,$J,358.4,2221,0)
 ;;=COGNITIVE ASSESS/CARE PLAN^2^166
 ;;^UTILITY(U,$J,358.4,2222,0)
 ;;=COLLABORATIVE CARE MGMT^3^166
 ;;^UTILITY(U,$J,358.4,2223,0)
 ;;=THERAPEUTIC INTVN^11^166
 ;;^UTILITY(U,$J,358.4,2224,0)
 ;;=TBI SCREENING^1^167
 ;;^UTILITY(U,$J,358.4,2225,0)
 ;;=MENTAL HEALTH^4^167
 ;;^UTILITY(U,$J,358.4,2226,0)
 ;;=NEUROLOGY^5^167
 ;;^UTILITY(U,$J,358.4,2227,0)
 ;;=HEADACHES^2^167
 ;;^UTILITY(U,$J,358.4,2228,0)
 ;;=HISTORY OF ILLNESS^3^167
 ;;^UTILITY(U,$J,358.4,2229,0)
 ;;=SIGNS, SYMPTOMS, CONDITIONS^6^167
 ;;^UTILITY(U,$J,358.4,2230,0)
 ;;=CAUSES OF INJURY (SECONDARY DX ONLY)^8^167
 ;;^UTILITY(U,$J,358.4,2231,0)
 ;;=SUICIDE IDEATIONS/ATTEMPTS^7^167
